ALTO NEUROSCIENCE INC (ANRO)
Health Care · Clinical-stage biopharmaceutical development · NYSE
A clinical-stage biotech company developing psychiatric and neurological treatments using proprietary biomarker discovery to identify and treat patient subpopulations.
What ALTO NEUROSCIENCE INC does
Alto Neuroscience is a clinical-stage biopharmaceutical company developing psychiatric and neurological therapeutics using a biomarker-driven platform. The company uses its proprietary Platform to gather biomarker data to guide development of product candidates including ALTO-100 and ALTO-300. Alto is currently in preclinical and early clinical development stages with no approved products or commercialization experience.
Themes: ["psychiatric therapeutics","neurological disorders","biomarker-driven drug development","clinical-stage biotech","companion diagnostics"]
Fundamentals
- Price$27.64 as of 2026-07-09 close
- Market cap$916M as of 2026-07-10
- 1-year return+943.6% as of 2026-07-09 close
- Net margin-4374.8% as of 2026-07-10
- ROE-47.2% as of 2026-07-10
- Debt / equity0.08 as of 2026-07-10
- Beta2.33 as of 2026-07-10
Key risks (from latest filing)
["Substantial additional financing required to continue development; failure to obtain capital could delay or terminate product development efforts","FDA may not agree with biomarker-based approach or companion diagnostic development could fail or face significant delays, materially harming the business","Product candidates may fail to obtain regulatory approval or achieve market acceptance, preventing commercialization and revenue generation"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.